AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25025611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analyses of predictors for lower 3- and 6-month GOS-E
Number of subjects: 386
Study 25025963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (up to 400 mg bid) plus liposomal doxorubicin (PLD) 40 mg m(-2)
Number of subjects: 44
Study 25025963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (up to 400 mg bid) plus PLD 40 mg m(-2)
Number of subjects: 44
Study 25027734 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese girls
Number of subjects: 73
Study 25027734 — intervention group
Group type: COMPARATOR
Intervention: Obese girls
Number of subjects: 73
Study 25027873 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF with anemia (group 1)
Number of subjects: 151
Study 25027873 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF without anemia (group 2)
Number of subjects: 151
Study 25027873 — intervention group
Group type: COMPARATOR
Intervention: Chronic kidney disease control group (group 3)
Number of subjects: 151
Study 25028353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (serum 25OHD < 50 nmol/L)
Number of subjects: 62
Study 25028353 — intervention group
Group type: COMPARATOR
Intervention: Sufficient Vitamin D (serum 25OHD ≥ 50 nmol/L)
Number of subjects: 62
Study 25028353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 62
Study 25028485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 1961
Study 25029231 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition assessment using the Patient-Generated Subjective Global Assessment (PG-SGA) questionnaire
Number of subjects: 210
Study 25029231 — intervention group
Group type: EXPERIMENTAL
Intervention: cGVHD of the lungs, gastrointestinal (GI) tract, and mouth, NIH global score, cGVHD symptoms, worse functioning, low albumin, poorer survival, and low BMI
Number of subjects: 210
Study 25029231 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on cGVHD of the lungs, GI tract, mouth, and BMI
Number of subjects: 210
Study 25029231 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-SGA questionnaire
Number of subjects: 210
Study 25029231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support interventions
Number of subjects: 210
Study 25029335 — intervention group
Group type: EXPERIMENTAL
Intervention: cGAMP stimulation of peripheral-blood mononuclear cells and fibroblasts from patients and controls
Number of subjects: 6
Study 25029335 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK inhibitors on lymphocytes from affected children
Number of subjects: 6
Study 25029335 — intervention group
Group type: EXPERIMENTAL
Intervention: HEK293T cells transfected with mutant STING constructs
Number of subjects: 6
Study 25029335 — intervention group
Group type: EXPERIMENTAL
Intervention: cGAMP exposure of endothelial cells
Number of subjects: 6
Study 25030780 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption >100 g/d
Number of subjects: 74645
Study 25030780 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed red meat consumption (100 g/d)
Number of subjects: 74645
Study 25030780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprocessed red meat consumption (high and moderate intakes)
Number of subjects: 74645
Study 25030780 — intervention group
Group type: COMPARATOR
Intervention: No red meat consumption
Number of subjects: 74645
Study 25030840 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral QLT091001 (10-40 mg/m(2) per day for 7 days)
Number of subjects: 14
Study 25032816 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment for 12 weeks
Number of subjects: 0
Study 25032995 — intervention group
Group type: EXPERIMENTAL
Intervention: diVIsive Shuffling Approach (VIStA)
Number of subjects: 140
Study 25034386 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (SAF measurement)
Number of subjects: 202
Study 25034386 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (SAF measurement)
Number of subjects: 202
Study 25034386 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients across GOLD stages (SAF measurement)
Number of subjects: 202
Study 25034386 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (association with lung function)
Number of subjects: 202
Study 25034977 — intervention group
Group type: EXPERIMENTAL
Intervention: plm60-s at 10 mg/m(2)
Number of subjects: 20
Study 25034977 — intervention group
Group type: EXPERIMENTAL
Intervention: plm60-s at 18 mg/m(2)
Number of subjects: 20
Study 25034977 — intervention group
Group type: COMPARATOR
Intervention: c-MI at 10 mg/m(2)
Number of subjects: 20
Study 25036269 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDs with or without CRT-D
Number of subjects: 0
Study 25036504 — intervention group
Group type: EXPERIMENTAL
Intervention: OSAHS patients during sleep
Number of subjects: 21
Study 25036504 — intervention group
Group type: COMPARATOR
Intervention: Normal controls during sleep
Number of subjects: 21
Study 25036713 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (1.6 nmol/kg, n = 2; 3.2 nmol/kg, n = 3; 6.4 nmol/kg, n = 24; 12.8 nmol/kg, n = 24)
Number of subjects: 53
Study 25036713 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54
Number of subjects: 53
Study 25037041 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin D insufficiency (<32 ng/mL)
Number of subjects: 352
Study 25037041 — intervention group
Group type: COMPARATOR
Intervention: ART-treated pregnant women
Number of subjects: 352
Study 25037144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus aripiprazole
Number of subjects: 292
Study 25037144 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI plus aripiprazole
Number of subjects: 292
Study 25037310 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute device implantation
Number of subjects: 39
Study 25037684 — intervention group
Group type: EXPERIMENTAL
Intervention: IV trebananib 15 mg/kg QW plus paclitaxel 175 mg/m(2) Q3W and carboplatin 6 mg/mL · min Q3W followed by trebananib 15 mg/kg QW monotherapy for 18 months
Number of subjects: 27
Study 25037759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis-informed counseling
Number of subjects: 151
Study 25037863 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous daily oral afatinib (30 mg starting dose, escalation to 50 mg) combined with intravenous pemetrexed (500 mg/m2)
Number of subjects: 53
Study 25037863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dose daily oral afatinib (50 mg starting dose, escalation to 70 mg) combined with intravenous pemetrexed (500 mg/m2)
Number of subjects: 53
Study 25037863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing schedules (SA and SB)
Number of subjects: 53
Study 25038014 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound (US)
Number of subjects: 28
Study 25038014 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT) scan
Number of subjects: 28
Study 25038354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin for 12 weeks
Number of subjects: 223
Study 25038354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and weight-based ribavirin for 24 weeks
Number of subjects: 223
Study 25038354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin treatment
Number of subjects: 223
Study 25038774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic presentations in the 90 days before AMI
Number of subjects: 16439
Study 25038774 — intervention group
Group type: COMPARATOR
Intervention: No prior ischaemic presentations
Number of subjects: 16439
Study 25038824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2, 2 h) + Irinotecan (125 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Number of subjects: 20
Study 25038824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2, 2 h) + Irinotecan (165 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Number of subjects: 20
Study 25038824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2, 2 h) + Irinotecan (95 mg/m2) + Oxaliplatin (85 mg/m2, 2 h) + FA (400 mg/m2, 2 h) + 5-FU (3200 mg/m2, 46 h) every two weeks.
Number of subjects: 20
Study 25039025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) measurement
Number of subjects: 840
Study 25039025 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for hypertension
Number of subjects: 840
Study 25039025 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for low high-density lipoprotein cholesterol
Number of subjects: 840
Study 25039025 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for divorced marital status
Number of subjects: 840
Study 25039696 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls with ASD
Number of subjects: 100
Study 25039696 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with ASD
Number of subjects: 100
Study 25039696 — intervention group
Group type: COMPARATOR
Intervention: Typically developing peers (control group)
Number of subjects: 100
Study 25040144 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,3-beta-d-glucan (BDG) testing prior to initiation of antifungal (AF) treatment
Number of subjects: 66
Study 25040144 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,3-beta-d-glucan (BDG) testing in patients who had undergone surgical procedures
Number of subjects: 66
Study 25040144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision based on BDG results
Number of subjects: 66
Study 25040462 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine 150 mg/day for 6 weeks
Number of subjects: 140
Study 25041850 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci SP Surgical System (single-port robotic surgery)
Number of subjects: 19
Study 25041904 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-RADS categorization of nodules recognized at CT or MRI
Number of subjects: 0
Study 25041904 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-RADS Management Working Group consensus
Number of subjects: 0
Study 25041904 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-RADS guidelines
Number of subjects: 0
Study 25042202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg per day plus R-CHOP
Number of subjects: 33
Study 25042419 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 2655
Study 25042419 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2655
Study 25042419 — intervention group
Group type: EXPERIMENTAL
Intervention: Killip class III or IV
Number of subjects: 2655
Study 25042419 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired left ventricular ejection fraction
Number of subjects: 2655
Study 25042419 — intervention group
Group type: EXPERIMENTAL
Intervention: Final TIMI flow 0-2
Number of subjects: 2655
Study 25042419 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 2655
Study 25042419 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2655
Study 25042419 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK
Number of subjects: 2655
Study 25042797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) at 120, 180, and 240 μg with ribavirin
Number of subjects: 0
Study 25042797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) at 240 μg with ribavirin
Number of subjects: 0
Study 25042797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) at all doses with ribavirin
Number of subjects: 0
Study 25042797 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a/ribavirin
Number of subjects: 0
Study 25043069 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg loading dose (LD)
Number of subjects: 840
Study 25043069 — intervention group
Group type: COMPARATOR
Intervention: 75 mg maintenance dose (MD)
Number of subjects: 840
Study 25043069 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg loading dose (LD) in CYP2C19 loss-of-function carriers
Number of subjects: 840
Study 25043069 — intervention group
Group type: COMPARATOR
Intervention: 75 mg maintenance dose (MD) in CYP2C19 loss-of-function carriers
Number of subjects: 840
Study 25043069 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg loading dose (LD) in CYP2C19 non-carriers
Number of subjects: 840
Study 25043069 — intervention group
Group type: COMPARATOR
Intervention: 75 mg maintenance dose (MD) in CYP2C19 non-carriers
Number of subjects: 840
Study 25043320 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (response at 4th week)
Number of subjects: 470
Study 25043320 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (remission at 12th week)
Number of subjects: 470
Study 25043320 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (response)
Number of subjects: 470
Study 25043483 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem magnetic resonance (PMMR) imaging
Number of subjects: 400
Study 25043483 — intervention group
Group type: COMPARATOR
Intervention: Conventional autopsy
Number of subjects: 400
Study 25043597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodybuilding HDS
Number of subjects: 839
Study 25043597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbodybuilding HDS
Number of subjects: 839
Study 25043597 — intervention group
Group type: COMPARATOR
Intervention: Medications
Number of subjects: 839
Study 25043869 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR levels in patient groups (initial level 18.8 ng/mL, range 6.8-30.1 ng/mL)
Number of subjects: 66
Study 25043869 — intervention group
Group type: COMPARATOR
Intervention: suPAR levels in control group (initial level 6.0 ng/mL, range 3.7-10.8 ng/mL)
Number of subjects: 66
Study 25043869 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels in patient groups
Number of subjects: 66
Study 25043869 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for suPAR
Number of subjects: 66
Study 25043869 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for CRP
Number of subjects: 66
Study 25043869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value for suPAR
Number of subjects: 66
Study 25045404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Program (DP)
Number of subjects: 100
Study 25045404 — intervention group
Group type: COMPARATOR
Intervention: Self-Selected Physical Activity Program (SSP)
Number of subjects: 100
Study 25045579 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-PDR
Number of subjects: 110
Study 25045579 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS II
Number of subjects: 110
Study 25045579 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 110
Study 25045579 — intervention group
Group type: EXPERIMENTAL
Intervention: pro-ADM
Number of subjects: 110
Study 25045579 — intervention group
Group type: EXPERIMENTAL
Intervention: copeptin
Number of subjects: 110
Study 25046246 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy and psychotherapy (cognitive behavioral therapy or psychoeducation)
Number of subjects: 160
Study 25047021 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 4789
Study 25047061 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests including PSA, free to total PSA, MRI of prostate, and prostate biopsy.
Number of subjects: 0
Study 25047061 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of a bio-bank of tissue, urine, and serum from the cohort.
Number of subjects: 0
Study 25047061 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of an inception cohort for future interventional studies.
Number of subjects: 0
Study 25047123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (E7080) administered twice daily in 3-week cycles; 2 weeks of treatment followed by 1 week of rest.
Number of subjects: 27
Study 25047658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 328
Study 25047658 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory II
Number of subjects: 328
Study 25047658 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between Pittsburgh Sleep Quality Index and Beck Depression Inventory II
Number of subjects: 328
Study 25047658 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with mild/moderate pain
Number of subjects: 328
Study 25047658 — intervention group
Group type: EXPERIMENTAL
Intervention: History of headaches
Number of subjects: 328
Study 25047658 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, body mass index, days of pain, severe acute painful events
Number of subjects: 328
Study 25047720 — intervention group
Group type: EXPERIMENTAL
Intervention: ModuLAAr Ambient Assisted Living system
Number of subjects: 0
Study 25047747 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy plus bevacizumab
Number of subjects: 2203
Study 25047979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5mg daily) with prednisone (for the first 3 cycles)
Number of subjects: 29
Study 25047979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide with prednisone
Number of subjects: 29
Study 25047992 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes non-acceptance (measured by the Acceptance and Action Diabetes Questionnaire)
Number of subjects: 320
Study 25047992 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-care/glycaemic control
Number of subjects: 320
Study 25048824 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 2886
Study 25048824 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 2886
Study 25049247 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg posaconazole once daily
Number of subjects: 54
Study 25049247 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg posaconazole once daily
Number of subjects: 54
Study 25049247 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole tablets
Number of subjects: 54
Study 25049249 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 25049249 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin (ART)-based combination therapies (ACTs)
Number of subjects: 0
Study 25050705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium gluconate (NaG)
Number of subjects: 154
Study 25050705 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG)
Number of subjects: 154
Study 25050705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sodium gluconate (NaG) and monosodium glutamate (MSG)
Number of subjects: 154
Study 25052051 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate 60 mg intravenous over 24 hours every 2 weeks
Number of subjects: 24
Study 25052451 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² on days 1 and 8 and cisplatin 70 mg/m² on day 1 every 21 days with lenalidomide 10 mg daily on days 1-14 (phase Ib).
Number of subjects: 9
Study 25052451 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin (GCL) regimen without lenalidomide (control group not explicitly mentioned but implied as standard treatment).
Number of subjects: 9
Study 25052720 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT-HT (Intensity Modulated Radiation Therapy delivered by helical tomotherapy)
Number of subjects: 30
Study 25052720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac myoview tests
Number of subjects: 30
Study 25052720 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month follow-up chest CT-scans
Number of subjects: 30
Study 25052720 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 30
Study 25053535 — intervention group
Group type: EXPERIMENTAL
Intervention: INCRAFT AAA Stent Graft System
Number of subjects: 60
Study 25053761 — intervention group
Group type: EXPERIMENTAL
Intervention: GATEp (prototype version of GATE)
Number of subjects: 30
Study 25053761 — intervention group
Group type: COMPARATOR
Intervention: GATEe (clinical trial version implemented in EyeSuite)
Number of subjects: 30
Study 25053761 — intervention group
Group type: EXPERIMENTAL
Intervention: GATEp
Number of subjects: 30
Study 25053761 — intervention group
Group type: COMPARATOR
Intervention: GATEe
Number of subjects: 30
Study 25053760 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaeth/Richman Contrast Sensitivity Test (SPARCS)
Number of subjects: 0
Study 25053760 — intervention group
Group type: COMPARATOR
Intervention: Pelli-Robson chart
Number of subjects: 0
Study 25054539 — intervention group
Group type: EXPERIMENTAL
Intervention: Right middle lobe (RML) contribution to emphysema (% low attenuation area, LAAinsp<-950 HU at end-inspiration)
Number of subjects: 0
Study 25054539 — intervention group
Group type: EXPERIMENTAL
Intervention: Right middle lobe (RML) contribution to gas trapping (%LAAexp<-856 HU at end-expiration)
Number of subjects: 0
Study 25054539 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of RML with spirometry
Number of subjects: 0
Study 25054539 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole lung CT metrics correlation with spirometry excluding RML
Number of subjects: 0
Study 25056132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients (2006 vs 2009)
Number of subjects: 0
Study 25056132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 0
Study 25056438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (CE) in BAT(+) group
Number of subjects: 12
Study 25056438 — intervention group
Group type: COMPARATOR
Intervention: Cold exposure (CE) in BAT(-) group
Number of subjects: 12
Study 25056500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 0
Study 25056500 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 0
Study 25056691 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAAs) ingestion (13 g; 2.4 g of Leu)
Number of subjects: 13
Study 25057165 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive locoregionally advanced (LA) disease
Number of subjects: 0